- Home
- AFRI vs CUE Comparison
AFRI vs CUE Comparison
Compare AFRI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRI | CUE |
|---|---|---|
| Founded | 1943 | 2014 |
| Country | Gibraltar | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 233.5M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AFRI | CUE |
|---|---|---|
| Price | $11.07 | $30.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 20.1K | ★ 149.3K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $8.13 | $0.17 |
| 52 Week High | $11.90 | $45.50 |
Technical Indicators
Market Signals| Indicator | AFRI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.59 |
| Support Level | N/A | $24.35 |
| Resistance Level | N/A | $32.50 |
| Average True Range (ATR) | 0.00 | 2.95 |
| MACD | 0.00 | 0.34 |
| Stochastic Oscillator | 0.00 | 70.66 |
Price Performance
Historical ComparisonAbout AFRI Forafric Global PLC
Forafric Global PLC is engaged in the production and sale of wheat flour, semolina, pasta, and couscous products. The company operates through the Soft Wheat, Durum Wheat, and Couscous & Pasta segments. Its main brands include MAYMOUNA and TRIA. It generates the majority of its revenue from the Soft Wheat segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.